Recently, the All-China Federation of Industry and Commerce announced the "2022-2023 China Medical Industry Most Influential List" at the China Medical Industry Development Forum. After a two-month evaluation process, RainMed Medical stood out among more than 1,000 participating companies and was awarded the “Pioneering Enterprise of Independent Innovation” and "Law-abiding and Honest Enterprise" honors along with leading companies in the industry such as HENGRUI, United Imaging Healthcare, and LEPU.

The China Medical Industry Development Forum is an authoritative brand event in China's medical industry. The event aims to promote industry development and invites top domestic expert teams to conduct comprehensive evaluations of enterprises in terms of research and development, production, service, reputation, and other aspects. This award indicates that the expert team widely recognizes RainMed Medical's strong comprehensive strength in its software and hardware, outstanding scientific research and innovation level, and profound clinical application value. It is believed that the large-scale clinical application of RainMed Medical's series of innovative products will promote the rapid development of precision medicine for vascular diseases in China.

As a national high-tech enterprise, RainMed Medical attaches great importance to domestic independent innovation, high-end talent cultivation, and global marketing promotion. Adhering to the purpose of "Targeted Medical Services for People's Health", RainMed Medical has continuously commercialized 2 innovative coronary functional diagnostic products, the caFFR system and the caIMR system. In addition, RainMed Medical has launched a vascular intervention surgical robot that covers the entire process of diagnosis and treatment, as well as cutting-edge vascular disease treatment technologies such as shock wave balloon catheters and renal artery ablation systems.

Among them, the caFFR system is one of the domestically produced FFR innovative assessment systems with the highest accuracy. The system does not require pressure wires, hyperemic agents, and additional surgical procedures. It only takes five minutes to get the result. Currently, the caFFR system has obtained three important medical device registration certificates including the EU CE, China NMPA, and Australia TGA, achieving the breakthrough of zero exports of domestically produced FFR products and providing accurate diagnosis of vascular disease for 30 provinces and regions in China, as well as 10 countries and regions worldwide.

The caIMR system is one of the world's first non-invasive coronary microcirculation dysfunction diagnostic systems approved for commercialization. Unlike traditional guidewire-derived IMR, the caIMR system does not require pressure wires and hyperemic agents and it does not require changes to the operator's surgical habits. It calculates the IMR value in just 5 minutes with an accuracy of 93.81%, which can replace guidewire-derived IMR and provide new opportunities for large-scale clinical applications of microcirculation assessment.

Currently, the caFFR system and the caIMR system are integrated into the FlashBot vascular disease surgical robot as the "eyes" of the robot system. In the future, the robot system will continue to integrate cutting-edge technologies such as shock wave balloon catheters and renal artery ablation, and use 5G internet and AI technology to provide remote and full-process automated solutions for complex vascular diseases. This will enable county-level medical institutions to enjoy high-quality medical services provided by large tertiary a-level hospitals, achieving the equalization of regional medical standards and contributing to the goal of a healthy China.